Repository logo
 

Engaging Cold to Upregulate Cell Proliferation in Alginate-Encapsulated Liver Spheroids.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Kilbride, P 
Mahbubani, KT 
Saeb-Parsy, Kourosh  ORCID logo  https://orcid.org/0000-0002-0633-3696
Morris, GJ 

Abstract

For many years, the impact of hyper- and hypothermia on mammalian cells has been examined. With the exception of short, low temperature storage, which has uses in areas such as preservation for transplantation or regenerative medicine, advantages for the use of low temperature treatment in hepatocytes have not been previously reported. We have observed that alginate-encapsulated HepG2 liver spheroids that are cryopreserved or experience a cold reduction in temperature (≤10°C) for periods between 1 and 90 min display an enhanced cell proliferation during culture 7-16 days post-treatment compared with untreated samples. Following 8-12 days post-treatment, alginate-encapsulated liver spheroids experienced a cell density of 1.71 ± 0.35 times that of control samples (p < 0.001). This effect occurred in samples with a variety of cold treatments. This low temperature treatment offers a simple method to rapidly increase cell proliferation rates for extended culture systems, such as bioartificial liver devices. This would allow the manufacture of required biomass more rapidly, and to a higher cell density, reducing final required biomass volume. This could enable bioartificial liver devices to be prepared more cheaply, making them a more cost effective treatment.

Description

Keywords

bioartificial liver, cell growth, hepatocytes, hypothermic

Journal Title

Tissue Engineering - Part C: Methods

Conference Name

Journal ISSN

1937-3384
1937-3392

Volume Title

23

Publisher

Mary Ann Liebert
Sponsorship
Medical Research Council (MC_PC_14124)
Funding for this work was provided through a Medical Research Council (United Kingdom) Industrial Case Studentship (9203) and by Innovate UK (101103) between University College London and Asymptote Ltd. and a Medical Research Council Proximity to Discovery Grant (RG79366) between University of Cambridge and Asymptote Ltd.